Most Read Articles
6 days ago
Intra-articular injections of botulinum toxin-A deliver substantial short-term benefits in terms of pain reduction in patients with refractory joint pain, according to a meta-analysis.
16 Aug 2017
At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.
Roshini Claire Anthony, 15 Jul 2017

Adding midostaurin to standard chemotherapy appeared to improve overall survival (OS) in patients recently diagnosed with acute myeloid leukaemia (AML) with a FLT3 mutation, according to a recent study.

Pearl Toh, 10 May 2017
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.

TNF-alpha medication ups risk of tuberculosis

05 Apr 2017

Patients treated with tumour necrosis factor (TNF)-α antagonists may be at a greater risk of tuberculosis (TB), although the biological mechanism underlying this association needs to be elucidated, according to a meta-analysis.

Researchers searched databases including Medline, Embase and Cochrane library for randomised controlled trials (RCTs) reporting TB risk among patients treated with any of the currently available TNF-α antagonists: etanercept (ETN), adalimumab (ADA), infliximab (IFX), golimumab (GOL) and certolizumab pegol (CZP). Exclusion criteria included studies based on unoriginal data, those without data on TB incidence, those that did not observe TB events and articles not published in English.

A total of 29 RCTs involving 11,879 patients were included (n=14 for IFX; n=9 for ADA; n=2 for GOL; n=1 for ETN; n=3 for CZP). A random-effect model was used to calculate odds ratios (ORs) with 95 percent CIs, and subgroup analyses were performed based on type of medication, disease under treatment and TB endemicity. Quality of evidence was evaluated using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.

Pooled data revealed that TB developed in 45 of 7,912 patients in the TNF-α arms and in three of 3,967 patients in the control arms, yielding an OR of 1.94 (1.10 to 3.44; p=0.02). Results from the subgroup analyses indicated that the effect of TNF-α treatment on TB risk was greater among patients treated for rheumatoid arthritis (OR, 2.29; 1.09 to 4.78; p=0.03). The quality of evidence was low as per the GRADE system.

The present data highlight the importance of considering the potential increase in the risk of TB in the clinical decision concerning treatment with anti-TNF-α drugs; patients should be screened for LTBI and anti-TB prophylaxis before making any decision.

TNF-α antagonists are widely used in in the treatment of rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis and other immune-mediated or inflammation-related diseases. These agents potentially impact on the protective mechanism against infections, especially TB, by increasing the phagocytic capacity of macrophages and enhancing intracellular killing of mycobacterium via the generation of reactive nitrogen and oxygen intermediates. [J Pathol 2008;214:149–60; Ann Rheum Dis 2015;74:1212–17]

“TNF-α is also involved in the pathological changes of latent tuberculous infection, especially in maintaining the formation and function of granuloma which prevents mycobacterium from disseminating into the blood. These TNF-mediated immune mechanisms may explain the reason for the increased risk of TB in patients receiving anti-TNF agents’ treatment,” researchers said.

“Further high-quality research regarding the long-term safety of biologics is needed to improve the safety of biological treatment in clinical use,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
6 days ago
Intra-articular injections of botulinum toxin-A deliver substantial short-term benefits in terms of pain reduction in patients with refractory joint pain, according to a meta-analysis.
16 Aug 2017
At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.
Roshini Claire Anthony, 15 Jul 2017

Adding midostaurin to standard chemotherapy appeared to improve overall survival (OS) in patients recently diagnosed with acute myeloid leukaemia (AML) with a FLT3 mutation, according to a recent study.

Pearl Toh, 10 May 2017
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.